Nektar Therapeutics
Profit Margins
| Period | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| Mar 2017 | 75.2% | -220.1% | -258.3% |
| Jun 2017 | 74.0% | -146.5% | -173.1% |
| Sep 2017 | 96.3% | 45.4% | 39.8% |
| Dec 2017 | 89.8% | -25.2% | -35.4% |
| Mar 2018 | 82.5% | -228.2% | -252.0% |
| Jun 2018 | 99.5% | 89.5% | 89.3% |
| Sep 2018 | 82.8% | -355.3% | -346.3% |
| Dec 2018 | 81.3% | -251.8% | -246.6% |
| Mar 2019 | 80.7% | -427.6% | -423.9% |
| Jun 2019 | 78.5% | -476.0% | -473.0% |
| Sep 2019 | 83.1% | -337.9% | -337.4% |
| Dec 2019 | 82.3% | -323.8% | -331.2% |
| Mar 2020 | 92.5% | -264.2% | -274.2% |
| Jun 2020 | 88.2% | -159.1% | -163.8% |
| Sep 2020 | 81.5% | -343.1% | -361.6% |
| Dec 2020 | 81.6% | -471.9% | -499.5% |
| Mar 2021 | 75.7% | -462.6% | -520.0% |
| Jun 2021 | 72.9% | -389.0% | -443.1% |
| Sep 2021 | 78.7% | -455.8% | -520.5% |
| Dec 2021 | 75.4% | -451.5% | -582.4% |
| Mar 2022 | 78.6% | -469.6% | -364.2% |
| Jun 2022 | 76.3% | -708.1% | -736.9% |
| Sep 2022 | 79.0% | -229.8% | -249.9% |
| Mar 2023 | 67.3% | -623.8% | -634.5% |
| Jun 2023 | 65.9% | -246.8% | -249.4% |
| Sep 2023 | 48.5% | -185.8% | -189.8% |
| Mar 2024 | 60.6% | -163.7% | -170.1% |
| Jun 2024 | 58.5% | -211.9% | -222.9% |
| Sep 2024 | 81.6% | -142.4% | -153.6% |
| Mar 2025 | 100.0% | -425.8% | -486.4% |
| Jun 2025 | 100.0% | -324.2% | -372.2% |
| Sep 2025 | 100.0% | -268.6% | -301.3% |
| Mar 2026 | — | -359.6% | -413.4% |
| Jun 2026 | — | -417.9% | -401.0% |